TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03198364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Augmentation
Description: Though a smartphone device, participants receive 12 weeks of personalized prompts derived from content produced in individual START sessions to increase transfer of skills to day to day life
Study: NCT03622437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-led follow-up
Description: 1. Patient-education, with information about signs of recurrent disease (alarm-symptoms), potential late effects, and how these can be managed.~2. The patients are instructed to contact a specialist nurse in case of alarm-symptoms, concerns or other problems related to the cancer disease throughout the entire follow-up period. The specialist nurse responds to the referrals, according to a standardized algorithm.~In addition, all patients receive:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years~Only for patients with a stoma:~- access to stoma care by specialist nurses

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Patients with sphincter-preserving resection:~- outpatient visits incl. rectoscopy at 6, 12, 18, 24 and 36 months~Patients with rectal amputation and a permanent stoma:~* outpatient visits at 3, 12 and 36 months~* access to stoma care by specialist nurses~All patients:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years
Study: NCT01564498

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vegetable
Description: 200-300 g raw carrots or 300-500 g cooked potatoes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vegetable
Description: 200-300 g raw carrots or 300-500 g cooked potatoes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vegetable
Description: 200-300 g raw carrots or 300-500 g cooked potatoes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vegetable
Description: 200-300 g raw carrots or 300-500 g cooked potatoes
Study: NCT02553148

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care
Study: NCT01132157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
Study: NCT02553148

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care
Study: NCT01132157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
Study: NCT04019314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Volume Analysis
Description: A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.
Study: NCT00410553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT01948232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril
Description: Angiotensin converting enzyme inhibitor
Study: NCT00039338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Radial hysterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy
Description: Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant chemotherapy
Description: Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: brachytherapy
Description: Brachytherapy at the end of external radiation. Minimal total dose (external with or without external boost + brachytherapy) of 75 Gy EQD2 to point A. Overall treatment less than 50 days.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Between 45-50 Gy, in fractions of 1.8 to 2 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).
Study: NCT03660306

Intervention type: PROCEDURE
Intervention: opioid anesthesia
Description: opioid anesthesia means using sufentanil during surgery

Intervention type: PROCEDURE
Intervention: opioid free anesthesia
Description: opioid free anesthesia means giving no opioids during surgery
Study: NCT01709929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
Study: NCT03288818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mechlorethamine Hydrochloride Gel
Description: Given topically

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Skin Electron Beam Radiation Therapy
Description: Undergo low dose (TSEBT) Total Skin Electron Beam Therapy
Study: NCT03785327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Participants either complete active and sham tDCS sessions one week apart or an autism training program.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Participants either complete active and sham tDCS sessions one week apart or an autism training program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism Training
Description: Autism Information Presentation developed by Dr. Grace Iarocci's Autism \& Developmental Disorders Lab at Simon Fraser University
Study: NCT02553148

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care
Study: NCT02198313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIX 1 XX - D3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00427739

Intervention type: PROCEDURE
Intervention: Cardiac CT
Description: 64 slice spiral computerized tomography
Study: NCT04353219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compression stocking
Description: participants will continue their training program as prepared by their coach with compression stocking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: participants will continue their training program as prepared by their coach without compression stocking
Study: NCT02425891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Description: Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Study: NCT03078933

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care arm which includes wound care, dressings and debridement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Therapy 2x week 6 min. plus standard of care
Description: Active Therapy Nitric Oxide delivered topically to the wound twice a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Therapy 2x week 12 min. plus standard of care
Description: Active Therapy Nitric Oxide delivered topically to the wound twice a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Therapy 4x week 6 min. plus standard of care
Description: Active Therapy Nitric Oxide delivered topically to the wound four times a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Therapy 4x week 12 min. plus standard of care
Description: Active Therapy Nitric Oxide delivered topically to the wound four times a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
Study: NCT02876497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Define macrophages migration mode
Description: Archival tumor samples analysis and blood sample testing
Study: NCT04076345

Intervention type: DIAGNOSTIC_TEST
Intervention: Prespesin assay on PATHFAST analyser
Description: Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence.

Intervention type: DIAGNOSTIC_TEST
Intervention: Prespesin assay on PATHFAST analyser
Description: Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence.

Intervention type: DIAGNOSTIC_TEST
Intervention: Prespesin assay on PATHFAST analyser
Description: Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence.
Study: NCT03844113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carnosine
Description: Each participant will be given a daily oral dose 2 g of carnosine for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will be given a daily oral dose 2 g of methycellulose powder for 6 months
Study: NCT05479929

Intervention type: OTHER
Intervention: Canadian Triage Assessment Scale (CTAS)
Description: The CTAS incorporates work of breathing into a subjective measurement in its assessment of patients and triaged.
Study: NCT01927640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine (0.3-0.6 mcg/kg) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline infusion (10 cc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine
Description: Intranasal cocaine (2 mg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal cocaine
Description: Intranasal cocaine (2 mg/kg)
Study: NCT01216644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2600 mg/m²d1 i.v. every 2 weeks
Study: NCT00468845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (Lyrica)
Description: 150 mg/day double blind (divided doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (Lyrica)
Description: 300 mg/day double blind (divided doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo
Description: matched placebo
Study: NCT01169584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Description: Intratumoral Injection Dosage from 1 x 10\^6 pfu/kg to 3 x 10\^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
Study: NCT03109691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: group 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: group 1
Study: NCT00957073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rheos® system
Description: Implant procedure
Study: NCT03872219

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Nature-based materials
Description: In the intervention arm, theycontain inactive and slowly-growing environmental bacteria and other microbiota. In the placebo arm, they do not contain the microbiota.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nature-based materials
Description: In the intervention arm, theycontain inactive and slowly-growing environmental bacteria and other microbiota. In the placebo arm, they do not contain the microbiota.
Study: NCT02864251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT03109691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: group 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: in all groups

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: in all groups
Study: NCT02547493

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcal polysaccharide vaccine
Description: Vaccination with PPSV on first day. NB : PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcal conjugate vaccine
Description: Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Abatacept started on frst day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Abatacept started on frst day
Study: NCT02553148

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care
Study: NCT00601913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein analysis
Study: NCT02553148

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care
Study: NCT00601913

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Study: NCT02553148

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care

Intervention type: OTHER
Intervention: Need for children's palliative care
Description: Need for children's palliative care
Study: NCT03479892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive once weekly injections of NNC0194-0499 matched placebo.
Study: NCT05503407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline V-RESOLVE score-guided PCI
Description: Jailed wire technique (JWT): Both main vessel (MV) and side branch (SB) are wired. The MV is stented with wire protection in SB. If suboptimal results exist, the SB would be rewired and a kissing balloon inflation (KBI) is undertaken.~Jailed balloon technique: A monorail balloon is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB.~Provisional two-stent strategy: Lesion preparation and MV stenting are consistent with JWT. Provisional SB stenting could be undertaken when suboptimal results occur after SB rewiring and a KBI is undertaken.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which usually stenting SB before MV stenting.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Angiography-guided PCI
Description: The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.
Study: NCT02255474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal D +1.50 add
Description: This is a monthly disposable contact lens commercially available from CooperVision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal D +2.50 add
Description: This is a monthly disposable contact lens commercially available from CooperVision

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofinity
Description: This is a monthly disposable spherical contact lens commercially available from CooperVision
Study: NCT00601913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Study: NCT04346784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maintaining positive working memory training
Description: Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: repressing negative working memory training
Description: Participants complete 10 sessions of repressing negative working memory training during a two-week period. Each session consists of 15 blocks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive ABMT
Description: Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
Study: NCT02864251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified days